Tempus AI Stock (TEM) Hits New 52-Week despite Analyst Downgrade
Tempus AI (TEM) stock surged 13.4% on Thursday, hitting a new 52-week high of $86. The upside came after the health ...
Artera partners with Tempus to expand AI cancer test access
Artera and Tempus are collaborating to expand access to Artera’s AI-based prostate cancer test. Currently connected to more ...
Tempus AI enters collaboration with Institute for Follicular Lymphoma Innovation
Tempus AI (TEM) announced a new collaboration with the Institute for Follicular Lymphoma Innovation. The collaboration aims to develop and make ...
Tempus Announces Collaboration with IFLI Aimed at Supporting Development of Targeted Therapies for Follicular Lymphoma
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...